References
Hong, H., Wang, Y., Chung, H.-T., & Chen, C.-J. (2020). Clinical characteristics of novel coronavirus disease 2019 (COVID-19) in newborns, infants and children. Pediatrics & Neonatology . https://doi.org/10.1016/j.pedneo.2020.03.001
Lang, J., Yang, N., Deng, J., Liu, K., Yang, P., Zhang, G., & Jiang, C. (2011). Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PloS One , 6 (8), e23710. https://doi.org/10.1371/journal.pone.0023710
Lu, Q., & Shi, Y. (2020). Coronavirus disease (COVID-19) and neonate: What neonatologist need to know. Journal of Medical Virology . https://doi.org/10.1002/jmv.25740
Ludvigsson, J. F. (2020). Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatrica (Oslo, Norway : 1992) . https://doi.org/10.1111/apa.15270
Song, R., Preston, G., & Yosypiv, I. V. (2012). Ontogeny of angiotensin-converting enzyme 2. Pediatric Research ,71 (1), 13–19. https://doi.org/10.1038/pr.2011.7
Wakabayashi, H., Oda, H., Yamauchi, K., & Abe, F. (2014). Lactoferrin for prevention of common viral infections. In Journal of Infection and Chemotherapy . https://doi.org/10.1016/j.jiac.2014.08.003
Wei, M., Yuan, J., Liu, Y., Fu, T., Yu, X., & Zhang, Z.-J. (2020). Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA . https://doi.org/10.1001/jama.2020.2131